World's Best Scientists 2026 revealed!
Véronique Diéras

Véronique Diéras

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 95 9874 9264 303 287 549 49750

Véronique Diéras publications per year

The chart shows the history of publications by Véronique Diéras between 1989 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Véronique Diéras published across 37 years, from 1989 to 2025, averaging 18.5 papers a year. Output peaked at 114 publications in 2023. 34 of the 684 publications appeared in the last two years.

No. of publications
25 50 75 100
Bar chart. Horizontal axis: year, 1989 to 2025. Vertical axis: number of publications, 0 to 114. Peak 114 publications in 2023. 1989: 2 publications 1990: 0 publications 1991: 0 publications 1992: 0 publications 1993: 1 publication 1994: 0 publications 1995: 6 publications 1996: 9 publications 1997: 6 publications 1998: 9 publications 1999: 9 publications 2000: 4 publications 2001: 12 publications 2002: 3 publications 2003: 7 publications 2004: 12 publications 2005: 6 publications 2006: 11 publications 2007: 14 publications 2008: 13 publications 2009: 28 publications 2010: 26 publications 2011: 23 publications 2012: 29 publications 2013: 28 publications 2014: 26 publications 2015: 19 publications 2016: 29 publications 2017: 39 publications 2018: 29 publications 2019: 28 publications 2020: 38 publications 2021: 42 publications 2022: 28 publications 2023: 114 publications 2024: 24 publications 2025: 10 publications
1989 2025

684 publications in total across all disciplines

View publications per year as a table
Véronique Diéras: publications per year, 1989 to 2025
Year Publications
1989 2
1990 0
1991 0
1992 0
1993 1
1994 0
1995 6
1996 9
1997 6
1998 9
1999 9
2000 4
2001 12
2002 3
2003 7
2004 12
2005 6
2006 11
2007 14
2008 13
2009 28
2010 26
2011 23
2012 29
2013 28
2014 26
2015 19
2016 29
2017 39
2018 29
2019 28
2020 38
2021 42
2022 28
2023 114
2024 24
2025 10
Total 684
Download as CSV

Véronique Diéras publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Véronique Diéras sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 541–560 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 549 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537 549
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Véronique Diéras D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Véronique Diéras sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 94–95 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 95 D-Index — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808 95
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Véronique Diéras is affiliated with the Institute Curie in France, focusing on oncology and breast cancer research. Their work spans the domains of medicine, with a particular emphasis on oncology, pulmonary and respiratory medicine, cancer research, genetics, and molecular biology.

Their research concentrates on multiple key topics including advanced breast cancer therapies, HER2/EGFR in cancer research, cancer treatment and pharmacology, breast cancer treatment studies, cancer immunotherapy and biomarkers, PARP inhibition in cancer therapy, and cancer genomics and diagnostics.

Frequent publication venues for their work include Annals of Oncology, Cancer Research, Journal of Clinical Oncology, European Journal of Cancer, and ESMO Open.

Coauthors who have regularly collaborated with Véronique Diéras include Hope S. Rugo, Javier Cortés, Delphine Loirat, Florence Dalenc, and Christelle Lévy.

Notable recent papers authored or coauthored by Véronique Diéras include:

  • Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial, 2020, The Lancet Oncology
  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer, 2021, New England Journal of Medicine
  • First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis, 2021, Annals of Oncology
  • Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial, 2023, Nature Medicine
  • Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study, 2021, JNCI Journal of the National Cancer Institute

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

    Peter Schmid;Stephen Y Chui;Leisha A Emens

  • Palbociclib and Letrozole in Advanced Breast Cancer

    Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones

  • 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    F. Cardoso;A. Costa;E. Senkus;M. Aapro

  • RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    Nicholas J. Robert;Véronique Diéras;John Glaspy;Adam M. Brufsky

  • Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Aditya Bardia;Sara A Hurvitz;Sara M Tolaney;Delphine Loirat

  • Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

    Stephen Johnston;John Pippen;Xavier Pivot;Mikhail Lichinitser

  • Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study

    Javier Cortes;Joyce O'Shaughnessy;David Loesch;Joanne J.L. Blum

  • Lapatinib Plus Capecitabine in Patients With Previously Untreated Brain Metastases From HER2-positive Metastatic Breast Cancer (LANDSCAPE): A Single-Group Phase 2 Study

    Thomas Bachelot;Gilles Romieu;Mario Campone;Véronique Diéras

  • Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer

    Nancy U Lin;Véronique Diéras;Devchand Paul;Dominique Lossignol

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    Maura N. Dickler;Sara Tolaney;Hope S. Rugo;Javier Cortés

  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

    Véronique Diéras;David Miles;Sunil Verma;Mark Pegram

  • Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

    Joanne L. Blum;Véronique Dieras;Patricia Mucci Lo Russo;John Horton

  • A New Model of Patient Tumor-Derived Breast Cancer Xenografts for Preclinical Assays

    Elisabetta Marangoni;Anne Vincent-Salomon;Nathalie Auger;Armelle Degeorges

  • 進行性乳癌のためのESO-ESMO国際コンセンサスガイドライン第四版(ABC 4)

    F Cardoso;E Senkus;A Costa;E Papadopoulos

  • Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER).

    Fabrice André;Fabrice André;Thomas Bachelot;Frederic Commo;Mario Campone

  • Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial

    Martine Piccart-Gebhart;Eileen Holmes;Jośe Baselga;Evandro De Azambuja

  • Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

    J Maltzman;Marck Pegram;Saeed Sadeghi;Cristina Oliva

Frequent Co-Authors

Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Jean-Yves Pierga
Jean-Yves Pierga Institute Curie
Mario Campone
Mario Campone Grenoble Alpes University
Javier Cortes
Javier Cortes Vall d'Hebron Hospital Universitari
Nadia Harbeck
Nadia Harbeck Ludwig-Maximilians-Universität München
Karen A. Gelmon
Karen A. Gelmon University of British Columbia
Bernard Asselain
Bernard Asselain Institute Curie
Richard S. Finn
Richard S. Finn University of California, Los Angeles
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Anne Vincent-Salomon
Anne Vincent-Salomon Institute Curie

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're drawn to the field of medicine but considering alternative pathways beyond a traditional MD program, there are several respected online degree options to explore. Many students pursue healthcare administration as a leadership-focused path, and the top online mha programs that are cahme accredited offer flexible options with rigorous standards.

Registered nurses looking to advance their credentials may be interested in online rn to bsn no clinicals pathways, which are tailored for working professionals and eliminate the requirement of additional in-person clinicals. For those already holding a master’s degree, the demand for advanced nurse practitioners has led to the emergence of the quickest dnp program tracks, helping you earn a Doctor of Nursing Practice in less time.

Affordability is also a growing concern for many students. Exploring the cheapest dnp programs can help you find budget-friendly options without compromising on quality. Online healthcare degrees can open doors to diverse roles in patient care, education, administration, and research—helping you make a real impact in the medical field.

Best Scientists Citing Véronique Diéras

Trending Scientists

Recently Published Articles